SIGY (Sigyn Therapeutics) Short-Term Capital Lease Obligation : $0.07 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Sigyn Therapeutics Short-Term Capital Lease Obligation?

Sigyn Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.07 Mil.

Sigyn Therapeutics's quarterly Short-Term Capital Lease Obligation increased from Sep. 2024 ($0.07 Mil) to Dec. 2024 ($0.07 Mil) and increased from Dec. 2024 ($0.07 Mil) to Mar. 2025 ($0.07 Mil).

Sigyn Therapeutics's annual Short-Term Capital Lease Obligation increased from Dec. 2022 ($0.05 Mil) to Dec. 2023 ($0.06 Mil) and increased from Dec. 2023 ($0.06 Mil) to Dec. 2024 ($0.07 Mil).

Sigyn Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Sigyn Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sigyn Therapeutics Short-Term Capital Lease Obligation Chart

Sigyn Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.05

0.06

0.07

Sigyn Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.06	0.07	0.07	0.07	0.07

Sigyn Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Sigyn Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Sigyn Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Sigyn Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sigyn Therapeutics Inc (OTCPK:SIGY) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106

Website

https://www.sigyntherapeutics.com

Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.

Executives

Joseph Segelman	director, 10 percent owner, officer: President & CEO	9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212
Australian Sapphire Corp	10 percent owner	9190 W OLYMPIC BLVD, BEVERLY HILLS CA 90212
Chaya Segelman	director, officer: Secretary	9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212